Regulus Therapeutics Inc. (NASDAQ:RGLS) has been given a consensus recommendation of “Hold” by the ten research firms that are currently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $4.50.

RGLS has been the topic of several research reports. Wedbush dropped their price objective on shares of Regulus Therapeutics from $8.00 to $6.00 and set an “outperform” rating on the stock in a research note on Monday, March 6th. BMO Capital Markets set a $1.00 price objective on shares of Regulus Therapeutics and gave the stock a “hold” rating in a research note on Monday, June 12th. Cantor Fitzgerald dropped their price objective on shares of Regulus Therapeutics from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Friday, March 3rd. Zacks Investment Research lowered shares of Regulus Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, March 8th. Finally, Cowen and Company reissued a “hold” rating on shares of Regulus Therapeutics in a research note on Friday, March 3rd.

COPYRIGHT VIOLATION NOTICE: “Regulus Therapeutics Inc. (RGLS) Receives Average Rating of “Hold” from Brokerages” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2017/06/19/regulus-therapeutics-inc-rgls-receives-average-rating-of-hold-from-brokerages.html.

Shares of Regulus Therapeutics (RGLS) traded down 4.2737% during trading on Monday, reaching $0.9094. 77,410 shares of the company traded hands. The firm’s 50 day moving average is $1.45 and its 200-day moving average is $1.69. Regulus Therapeutics has a 12-month low of $0.86 and a 12-month high of $5.95. The stock’s market capitalization is $48.36 million.

In other news, Director Stelios Papadopoulos bought 500,000 shares of the company’s stock in a transaction dated Wednesday, March 22nd. The shares were purchased at an average price of $1.22 per share, for a total transaction of $610,000.00. Following the completion of the purchase, the director now owns 400,677 shares in the company, valued at approximately $488,825.94. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 2.30% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. A.R.T. Advisors LLC increased its position in shares of Regulus Therapeutics by 405.0% in the fourth quarter. A.R.T. Advisors LLC now owns 90,400 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 72,500 shares in the last quarter. Tudor Investment Corp Et Al purchased a new position in shares of Regulus Therapeutics during the fourth quarter valued at about $105,000. Teachers Advisors LLC increased its position in shares of Regulus Therapeutics by 15.7% in the fourth quarter. Teachers Advisors LLC now owns 72,273 shares of the biopharmaceutical company’s stock valued at $163,000 after buying an additional 9,804 shares in the last quarter. Wells Fargo & Company MN increased its position in shares of Regulus Therapeutics by 13.5% in the first quarter. Wells Fargo & Company MN now owns 782,380 shares of the biopharmaceutical company’s stock valued at $1,291,000 after buying an additional 93,295 shares in the last quarter. Finally, Wedbush Securities Inc. increased its position in shares of Regulus Therapeutics by 106.8% in the first quarter. Wedbush Securities Inc. now owns 180,921 shares of the biopharmaceutical company’s stock valued at $299,000 after buying an additional 93,420 shares in the last quarter. Hedge funds and other institutional investors own 38.56% of the company’s stock.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Receive News & Ratings for Regulus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.